Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?
- 1 May 1997
- journal article
- review article
- Published by Elsevier BV in Trends in Pharmacological Sciences
- Vol. 18 (5), 164-170
- https://doi.org/10.1016/s0165-6147(97)01049-3
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Phosphodiesterase 4 and tolerance to β2-adrenoceptor agonists in asthmaTrends in Pharmacological Sciences, 1996
- Agents That Elevate cAMP Inhibit Human Neutrophil ApoptosisBiochemical and Biophysical Research Communications, 1995
- Delayed protection of the heart against ischaemiaTrends in Pharmacological Sciences, 1995
- Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in Brown-Norway ratsInflammation Research, 1995
- A novel insulin secretagogue is a phosphodiesterase inhibitorDiabetes, 1995
- Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitorInternational Journal of Immunopharmacology, 1994
- ApoptosisImmunology Today, 1993
- Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 1993
- The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune responseImmunology Today, 1988
- The Value of Maintenance Theophylline in Steroid-Dependent AsthmaNew England Journal of Medicine, 1981